Smithkline Beecham Plc & Ors v Apotex Europe Ltd & Ors [2005] EWHC 1655 (Ch) (26 July 2005)
The cross-undertaking in damages cannot be amended under the slip rule to retrospectively benefit the Canadian companies, as the form of the undertaking was deliberately agreed and accepted by the parties and the court. The joinder of the Canadian companies as defendants would not entitle them to retrospective benefit under the cross-undertaking. Claims based on estoppel by convention may proceed to trial, but restitutionary and third-party loss claims are not legally sustainable in this context.
- Citation
- [2005] EWHC 1655 (Ch)
- Parties
- Claimant (respondent on the Enquiry on the Cross Undertaking): SmithKline Beecham plc; Claimant (respondent on the Enquiry on the Cross Undertaking): GlaxoSmithKline UK Limited; Claimant (respondent on the Enquiry on the Cross Undertaking): Glaxo Group Ltd; Defendant (claimant on the Enquiry on the Cross Undertaking): Apotex Europe Limited; Defendant (claimant on the Enquiry on the Cross Undertaking): Neolab Limited; Defendant (claimant on the Enquiry on the Cross Undertaking): Waymade Healthcare plc; Additional Claimant on the Enquiry on the Cross Undertaking: Apotex Inc.; Additional Claimant on the Enquiry on the Cross Undertaking: Apotex Pharmachem Inc.
- Jurisdiction
- England and Wales
- Judgment Date
- 26 July 2005
- Procedural Posture
- Patents/injunctions/cross Undertaking in Damages / Interlocutory Applications and Summary Judgment/strike Out
- Outcome
- Applications to amend the cross-undertaking and for joinder of Canadian companies dismissed; application to strike out estoppel by convention claim refused; restitution and third-party loss claims struck out.
- Legal Topics
- Patents, Interim Injunctions, Cross Undertaking in Damages, Slip Rule, Joinder of Parties, Estoppel by Convention, Restitution, Third Party Loss
Case Brief
Summary, issues, holding and outcome
More case intelligence is available
Unlock the full research layer for this judgment.
Parties
SmithKline Beecham plc
Claimant (respondent on the Enquiry on the Cross Undertaking)
GlaxoSmithKline UK Limited
Claimant (respondent on the Enquiry on the Cross Undertaking)
Glaxo Group Ltd
Claimant (respondent on the Enquiry on the Cross Undertaking)
Apotex Europe Limited
Defendant (claimant on the Enquiry on the Cross Undertaking)
Neolab Limited
Defendant (claimant on the Enquiry on the Cross Undertaking)
Waymade Healthcare plc
Defendant (claimant on the Enquiry on the Cross Undertaking)
Apotex Inc.
Additional Claimant on the Enquiry on the Cross Undertaking
Apotex Pharmachem Inc.
Additional Claimant on the Enquiry on the Cross Undertaking
Procedural Posture
Patents/injunctions/cross Undertaking in Damages / Interlocutory Applications and Summary Judgment/strike Out
Legal Issues
- 1 Whether the cross-undertaking in damages should be amended under the slip rule to benefit additional parties
- 2 Whether additional parties (Canadian companies) should be joined to the action to benefit from the cross-undertaking
- 3 Whether the draft Points of Claim disclose a reasonable cause of action or have a real prospect of success regarding the Canadian companies' claims under the cross-undertaking
Ratio Decidendi
The cross-undertaking in damages cannot be amended under the slip rule to retrospectively benefit the Canadian companies, as the form of the undertaking was deliberately agreed and accepted by the parties and the court. The joinder of the Canadian companies as defendants would not entitle them to retrospective benefit under the cross-undertaking. Claims based on estoppel by convention may proceed to trial, but restitutionary and third-party loss claims are not legally sustainable in this context.
Court Disposition
Applications to amend the cross-undertaking and for joinder of Canadian companies dismissed; application to strike out estoppel by convention claim refused; restitution and third-party loss claims struck out.
Orders
- Application under the slip rule dismissed
- Joinder application dismissed
Full Case Text
Judgment text and source record
Sign in to read
Sign in to read the full judgment text
Sign in to read the full judgment text. Downloads and additional research tools may depend on your plan.
Sign in to read the full judgment